ExploreWatchlistsPricing
  1. JP-listed companies
  2. Momotaro-Gene Inc.
  3. Financials
  4. Total non-current liabilities

Momotaro-Gene Inc. (E33052)

Market cap
P/E ratio
Momotaro Genen develops innovative gene therapy drugs using the REIC cancer suppressor gene discovered at Okayama University to selectively kill cancer cells.
SummaryFinancialsDividendsHistoryWorkforce
Period EndTotal non-current liabilities (Million JPY)YoY (%)
Mar 31, 202319+20.07%
Mar 31, 202216+15.76%
Mar 31, 202114-64.56%
Mar 31, 202039-33.12%
Mar 31, 201959+0.70%
Mar 31, 201858+46.12%
Mar 31, 201740+100.00%
Mar 31, 201620+0.00%
Mar 31, 201520+0.00%
Mar 31, 201420+Infinity%
Mar 31, 20130NaN%
Mar 31, 20120NaN%
Mar 31, 20110NaN%
Mar 31, 20100NaN%
Mar 31, 20090

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat